Pharmaceutical Executive-02-01-2018

Pharm Exec chronicles the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader-a C-suite must in reviving the industry’s beleaguered reputation.

The biotech sector has managed to elude the negative perceptions saddling traditional pharma these days. We examine the reasons why.

Richard Lajoie, the new head of Valeant Canada, shares his main priorities for the business, including growing its domestic manufacturing as a key cog globally.

Low-cost follow-ons and biosimilars please payers but heighten competitive battles with brands.

Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders-call it the quest to see "what right looks like?"

2017 was a year of swings and momentum for the pharma and biotech markets. Is more stable footing ahead?

Click the title above to open the Pharmaceutical Executive February 2018 issue in an interactive PDF format.